Dasatinib Attenuates Fibrosis in Keloids by Decreasing Senescent Cell Burden

Overview

Journal Acta Derm Venereol

Specialty Dermatology

Date 2023 Apr 6

PMID 37021598

Authors

Claudia C Darmawan

Keunyoung Hur

Novi Kusumaningrum

Jin Ho Chung

Si-Hyung Lee

Je-Ho Mun

Affiliations

Soon will be listed here.

Abstract

Keloids are skin tumours caused by aberrant growth of dermal fibroblasts. Cellular senescence contributes to aging and various pathological conditions, including cancer, atherosclerosis, and fibrotic diseases. However, the effects of cellular senescence and senolytic drugs on keloids remain largely unknown. This study investigated senescent fibroblasts in keloids and assessed the effects of dasatinib on these cells. Tissues acquired from keloid removal surgery were analysed for senescence-associated β-galactosidase-positive cells, p16 expression, and the effects of dasatinib treatment on keloids. Keloid tissue was xenotransplanted into mice, and the effect of intralesional dasatinib injection on keloid growth was observed. The results showed that the numbers of β-galactosidase-positive and p16-expressing cells were higher in the keloids compared with in the controls. Dasatinib induced selective clearance of senescent cells and decreased procollagen expression in cultured keloid fibroblasts. In this xenotransplant keloid mouse model, intralesional injection of dasatinib reduced gross keloid tissue weight and the expression of both procollagen and p16. In addition, dasatinib-treated keloid fibroblasts conditioned medium reduced procollagen and p16 expression in cultured keloid fibroblasts. In conclusion, these results suggest that an increased number of senescent fibroblasts may play an important role in the pathogenesis of keloids. Therefore, dasatinib could be an alternative treatment for patients with keloids.

Citing Articles

Direct fibroblast reprogramming: an emerging strategy for treating organic fibrosis.

Lin H, Wang X, Chung M, Cai S, Pan Y J Transl Med. 2025; 23(1):240.

PMID: 40016790 PMC: 11869441. DOI: 10.1186/s12967-024-06060-3.

FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.

Kong Y, Li Z, Liu Y, Pan B, Fu X, Xiao R Commun Biol. 2025; 8(1):299.

PMID: 39994346 PMC: 11850796. DOI: 10.1038/s42003-025-07738-0.

References

Limandjaja G, Belien J, Scheper R, Niessen F, Gibbs S . Hypertrophic and keloid scars fail to progress from the CD34 /α-smooth muscle actin (α-SMA) immature scar phenotype and show gradient differences in α-SMA and p16 expression. Br J Dermatol. 2019; 182(4):974-986. DOI: 10.1111/bjd.18219. View

Martyanov V, Whitfield M, Varga J . Senescence Signature in Skin Biopsies From Systemic Sclerosis Patients Treated With Senolytic Therapy: Potential Predictor of Clinical Response?. Arthritis Rheumatol. 2019; 71(10):1766-1767. PMC: 7863581. DOI: 10.1002/art.40934. View

Xiao M, Chen W, Wang C, Wu Y, Zhu S, Zeng C . Senescence and cell death in chronic liver injury: roles and mechanisms underlying hepatocarcinogenesis. Oncotarget. 2018; 9(9):8772-8784. PMC: 5823588. DOI: 10.18632/oncotarget.23622. View

Li B, He F, Yang X, Chen Y, Fan J . Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Transl Res. 2016; 180:103-117.e4. DOI: 10.1016/j.trsl.2016.08.006. View

Zhu Y, Tchkonia T, Pirtskhalava T, Gower A, Ding H, Giorgadze N . The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015; 14(4):644-58. PMC: 4531078. DOI: 10.1111/acel.12344. View

Shah N, Kantarjian H, Kim D, Rea D, Dorlhiac-Llacer P, Milone J . Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26(19):3204-12. DOI: 10.1200/JCO.2007.14.9260. View

Yanaba K, Komura K, Kodera M, Matsushita T, Hasegawa M, Takehara K . Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis. 2005; 65(1):124-6. PMC: 1797996. DOI: 10.1136/ard.2005.040782. View

Zhang C, Hu X, Qi F, Luo J, Li X . Identification of , and as potential therapeutic target genes for renal interstitial fibrosis. Ann Transl Med. 2019; 7(18):454. PMC: 6803237. DOI: 10.21037/atm.2019.08.62. View

Schafer M, Haak A, Tschumperlin D, LeBrasseur N . Targeting Senescent Cells in Fibrosis: Pathology, Paradox, and Practical Considerations. Curr Rheumatol Rep. 2018; 20(1):3. DOI: 10.1007/s11926-018-0712-x. View

10.

Ong V, Evans L, Shiwen X, Fisher I, Rajkumar V, Abraham D . Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum. 2003; 48(7):1979-91. DOI: 10.1002/art.11164. View

11.

Martyanov V, Kim G, Hayes W, Du S, Ganguly B, Sy O . Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS One. 2017; 12(11):e0187580. PMC: 5679625. DOI: 10.1371/journal.pone.0187580. View

12.

Lee H, Jang Y . Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids. Int J Mol Sci. 2018; 19(3). PMC: 5877572. DOI: 10.3390/ijms19030711. View

13.

Varmeh S, Egia A, McGrouther D, Tahan S, Bayat A, Pandolfi P . Cellular senescence as a possible mechanism for halting progression of keloid lesions. Genes Cancer. 2012; 2(11):1061-6. PMC: 3379565. DOI: 10.1177/1947601912440877. View

14.

Roos C, Zhang B, Palmer A, Ogrodnik M, Pirtskhalava T, Thalji N . Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell. 2016; 15(5):973-7. PMC: 5013022. DOI: 10.1111/acel.12458. View

15.

Justice J, Nambiar A, Tchkonia T, LeBrasseur N, Pascual R, Hashmi S . Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019; 40:554-563. PMC: 6412088. DOI: 10.1016/j.ebiom.2018.12.052. View

16.

Childs B, Gluscevic M, Baker D, Laberge R, Marquess D, Dananberg J . Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. 2017; 16(10):718-735. PMC: 5942225. DOI: 10.1038/nrd.2017.116. View

17.

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

18.

Darmawan C, Montenegro S, Jo G, Kusumaningrum N, Lee S, Chung J . Adiponectin-Based Peptide (ADP355) Inhibits Transforming Growth Factor-β1-Induced Fibrosis in Keloids. Int J Mol Sci. 2020; 21(8). PMC: 7215791. DOI: 10.3390/ijms21082833. View

19.

Kirkland J, Tchkonia T, Zhu Y, Niedernhofer L, Robbins P . The Clinical Potential of Senolytic Drugs. J Am Geriatr Soc. 2017; 65(10):2297-2301. PMC: 5641223. DOI: 10.1111/jgs.14969. View

20.

Carlos Montero J, Seoane S, Ocana A, Pandiella A . Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011; 17(17):5546-52. DOI: 10.1158/1078-0432.CCR-10-2616. View